Meritage Pharma Reports Positive Phase 2b Data for Oral Budesonide Suspension in Pediatric Patients with Eosinophilic Esophagitis

Wednesday, May 11, 2011 General News J E 4
Data Presented at Digestive Disease Week Highlight OBS in Chronic Inflammatory Condition

Efficacy Parameter

Placebo N=18

Low Dose N=17

Medium Dose N=19

High Dose N=17

% Responders (Peak EOS =6/HPF + >50% Symptom Score Reduction) - p-value (OBS vs Placebo)

5.6 –

11.8 0.5282

52.6 0.0092

47.1 0.0174

% Subjects with Histologic Response (Peak EOS <6/HPF) - p-value (OBS vs Placebo)

5.6 –

23.5 0.1786

52.6 0.0090

94.1 0.0001

% Subjects with Histologic Remission (Peak EOS <1/HPF) - p-value (OBS vs Placebo)

0 –

11.8 0.4597

42.1 0.0042

76.5 <0.0001



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Rapid Fire Marketing's Medical Cannabis Management...
Pfenex Announces Strategic Collaboration With MedI...